Premium
Captopril treatment: inter‐dose variations in renin, angiotensins I and II, aldosterone and blood pressure.
Author(s) -
Atkinson AB,
Cumming AM,
Brown JJ,
Fraser R,
Leckie B,
Lever AF,
Morton JJ,
Robertson JI
Publication year - 1982
Publication title -
british journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.216
H-Index - 146
eISSN - 1365-2125
pISSN - 0306-5251
DOI - 10.1111/j.1365-2125.1982.tb01878.x
Subject(s) - captopril , renin–angiotensin system , plasma renin activity , aldosterone , medicine , endocrinology , angiotensin ii , blood pressure , chemistry , angiotensin converting enzyme
1 The ability of captopril, 150 mg three times daily by mouth, to effect sustained reduction in plasma angiotensin II, with converse increases in circulating angiotensin I, and in active, inactive and total renin concentrations, has been assessed. 2 During prolonged treatment with captopril alone, and 12 h after the last dose of the drug, plasma angiotensin II remained approximately one‐sixth of basal concentrations, while angiotensin I and renin concentrations were proportionately increased. However, further increases in angiotensin I, and in active, inactive and total renin concentrations, were seen 2 and 6 h after the morning dose of 150 mg captopril. 3 Inter‐dose variations in plasma aldosterone and blood pressure were not closely related to concurrent variations in the renin‐angiotensin system. 4 Arguments are presented for relying on measurements of plasma renin and angiotensin concentrations rather than of renin activity or aldosterone in assessing the effectiveness of converting enzyme inhibition.